Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

509 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early hepatic decompensation identifies patients with hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab or Sorafenib at highest risk of death.
Cabibbo G, Celsa C, Battaglia S, Enea M, Di Maria G, Grova A, Ciccia R, Manfredi GF, Iavarone M, Vogel A, Singal AG, Reig M, Pinato DJ, Cammà C. Cabibbo G, et al. Among authors: battaglia s. Clin Cancer Res. 2024 Nov 22. doi: 10.1158/1078-0432.CCR-24-2582. Online ahead of print. Clin Cancer Res. 2024. PMID: 39576248
First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials.
Cabibbo G, Reig M, Celsa C, Torres F, Battaglia S, Enea M, Rizzo GEM, Petta S, Calvaruso V, Di Marco V, Craxì A, Singal AG, Bruix J, Cammà C. Cabibbo G, et al. Among authors: battaglia s. Liver Cancer. 2021 Nov 23;11(1):75-84. doi: 10.1159/000520278. eCollection 2022 Jan. Liver Cancer. 2021. PMID: 35222509 Free PMC article.
Systemic therapies for hepatocellular carcinoma: the present and the future.
Celsa C, Giuffrida P, Stornello C, Grova M, Spatola F, Rizzo GEM, Busacca A, Cannella R, Battaglia S, Cammà C, Cabibbo G. Celsa C, et al. Among authors: battaglia s. Recenti Prog Med. 2021 Feb;112(2):110-116. doi: 10.1701/3559.35371. Recenti Prog Med. 2021. PMID: 33624623 Review.
RESIST-HCV Criteria to Monitor Progression of Low-Risk Esophageal Varices in Patients With Compensated Cirrhosis After HCV Eradication: The SIMPLE Study: SIMPLE: Scoring Index to Monitor Progression of Low-risk Esophageal varices.
Calvaruso V, Celsa C, D'Ambrosio R, Simone F, Petta S, Cacciola I, Enea M, Battaglia S, Pandolfo A, Licata M, Degasperi E, Cabibbo G, Di Marco L, Pennisi G, Borghi M, Di Martino V, Filomia R, Abdel-Hadi Y, Crapanzano L, Raimondo G, Lampertico P, Craxì A, Cammà C, Di Marco V. Calvaruso V, et al. Among authors: battaglia s. Am J Gastroenterol. 2022 Nov 1;117(11):1816-1824. doi: 10.14309/ajg.0000000000001878. Epub 2022 Jul 21. Am J Gastroenterol. 2022. PMID: 35973181
Mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis: A validated prediction model.
Vizzutti F, Celsa C, Calvaruso V, Enea M, Battaglia S, Turco L, Senzolo M, Nardelli S, Miraglia R, Roccarina D, Campani C, Saltini D, Caporali C, Indulti F, Gitto S, Zanetto A, Di Maria G, Bianchini M, Pecchini M, Aspite S, Di Bonaventura C, Citone M, Guasconi T, Di Benedetto F, Arena U, Fanelli F, Maruzzelli L, Riggio O, Burra P, Colecchia A, Villa E, Marra F, Cammà C, Schepis F. Vizzutti F, et al. Among authors: battaglia s. Hepatology. 2023 Feb 1;77(2):476-488. doi: 10.1002/hep.32704. Epub 2022 Aug 17. Hepatology. 2023. PMID: 35921493
509 results